Company news

Alector, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alector to Participate in the BofA Securities 2023 Healthcare Conference

May 1, 2023

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 27, 2023

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

December 7, 2022

Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

November 28, 2022

Alector Reports Third Quarter 2022 Financial Results and Provides Business Update

November 7, 2022

Alector Announces Promotion of Clare Hunt to Chief People Officer

October 12, 2022

Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer’s Disease (AD)

September 11, 2022

Alector Reports Second Quarter 2022 Financial Results and Provides Business Update

August 3, 2022

Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

June 7, 2022

Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules

May 26, 2022

Alector Reports First Quarter 2022 Financial Results and Provides Business Update

May 4, 2022

Alector to Participate at the BofA Securities 2022 Healthcare Conference

May 3, 2022

Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

March 28, 2022

Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial

March 14, 2022

Alector to Present at Upcoming Healthcare Conferences

March 8, 2022

Alector to Present New AL001 Data at AD/PD™ 2022

March 7, 2022

Alector to Participate at the Cowen 42nd Annual Health Care Conference

February 28, 2022

Alector Reports Fourth Quarter and Full Year 2021 Financial Results

February 23, 2022

Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer

February 6, 2022

Alector Announces Appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development

December 14, 2021

Alector Presents Preclinical Data from AL009 Multi-Siglec Inhibitor Program at the Society for Immunotherapy of Cancer’s 36th Annual Meeting

November 11, 2021

Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of INFRONT-2 Phase 2 Open-label Clinical Study

November 11, 2021

Alector Presents New Data from Multiple Pipeline Programs at 2021 CTAD Conference

November 9, 2021

Alector to Present at the Stifel 2021 Virtual Healthcare Conference

November 7, 2021

Alector Reports Third Quarter 2021 Financial Results

November 3, 2021

Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting

November 2, 2021

Alector Announces Appointment of Elizabeth A. Garofalo, M.D., to its Board of Directors

September 27, 2021

Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotrophic Lateral Sclerosis (ALS)

September 8, 2021

Alector to Present at Upcoming Virtual Healthcare Conferences

September 1, 2021

Alector Reports Second Quarter 2021 Financial Results

August 2, 2021

Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation

July 28, 2021

Alector to Present New Data from Frontotemporal Dementia and Alzheimer’s Disease Programs at the 2021 Alzheimer’s Association International Conference

July 20, 2021

Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases

July 1, 2021

CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia

June 1, 2021

Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021

May 25, 2021

Alector to Present at the BofA Securities 2021 Virtual Health Care Conference

May 5, 2021

Alector Reports 2021 First Quarter Financial Results and Provides Business Update

May 4, 2021

Alector to Present at Stifel’s 3rd Annual CNS Day

March 24, 2021

Alector to Present at the Barclays Global Healthcare Conference

March 3, 2021

Alector Reports 2020 Fourth Quarter and Full Year Financial Results and Provides Business Update

February 24, 2021

Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease

January 24, 2021

Alector Announces Departure of Chief Business Officer

January 19, 2021

Alector Provides 2021 Corporate Portfolio Update

January 6, 2021

Alector to Present at the Stifel 2020 Virtual Healthcare Conference

November 10, 2020

Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 9, 2020

Alector Provides Update on Arbitration Proceedings with Dr. Asa Abeliovich

November 1, 2020

Alector to Highlight Early-Stage Cancer Programs at Upcoming Scientific Forums

October 21, 2020

Alector to Participate at Virtual Investor Conferences in September

September 2, 2020

Alector Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 10, 2020

Alector to Present at the BTIG Virtual Biotechnology Conference 2020

August 3, 2020

← Newer news releases · Older news releases →

Calls

Decks